ORANGE, Calif., July 06, 2022 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled Medicare Advantage company, will release its second quarter 2022 financial results on Thursday, Aug. 4, 2022, after market close. Following the release, the company will host a conference call to review its financial results at 6 p.m. EDT.
Conference Call Details
Participants may pre-register for the conference call at the following link:
https://register.vevent.com/register/BI2c25ae8938554eedb99f028a75720193
Upon registration, participants will receive conferencing details, including the dial-in number and a unique participant ID. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same web link and will remain available for approximately 12 months.
About Alignment Healthcare
Alignment Healthcare is a consumer-centric platform delivering customized health care in the United States to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. The company provides partners and patients with customized care and service where they need it and when they need it, including clinical coordination, risk management and technology enablement. Alignment Healthcare offers health plan options through Alignment Health Plan, and also partners with select health plans to help deliver better benefits at lower costs.
Investor Contact
Harrison Zhuo
hzhuo@ahcusa.com
Media Contact
Maggie Habib
mPR, Inc. for Alignment Healthcare
alignment@mpublicrelations.com
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…
BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…
PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…
STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation…